Phase I/II Clinical Trial of Autologous Activated Platelet-Rich Plasma (aaPRP) in the Treatment of Severe Coronavirus Disease 2019 (COVID-19) Patients

Table 3

Primary outcomes of the patients.

Outcomes	aaPRP treatment
Hospitalization
Median duration of all patients from initial hospitalization in emergency room to ward room, days	4 (1 to 8)
Median duration of all patients in ICU, days	9 (5 to 16)
Median duration of among patients from emergency room and ward room to ICU who recovered, days	17 (10 to 23)
Oxygen
No. of patients/total no. (%)	10/10 (100)
Type of oxygen support, no./total no. (%)
NRM	2/10 (20)
HFNC	5/10 (50)
Ventilator	3/10 (30)
Median days receiving oxygen–days
NRM	5 (4 to 6)
HFNC	9 (7 to 14)
Ventilator	6 (3 to 6)
Recovery
No. of recoveries, %	9/10 (90)
Median time to recovery, days	9 (5 to 16)
Mortality
No of deaths, %	1/10 (10)
Median time to passed away, days	8
Main cause of mortality
Heart failure, %	1/1 (100)